Oxford Review of Education

Taylor & Francis
Taylor & Francis
ISSN: 03054985, 14653915

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
SCImago
Q1
WOS
Q1
Impact factor
2.3
SJR
0.987
CiteScore
5.2
Categories
Education
Areas
Social Sciences
Years of issue
1975-2025
journal names
Oxford Review of Education
OXFORD REV EDUC
Publications
1 971
Citations
33 165
h-index
75
Top-3 citing journals
Top-3 organizations
University of Oxford
University of Oxford (80 publications)
University of Cambridge
University of Cambridge (35 publications)
University of Birmingham
University of Birmingham (27 publications)
Top-3 countries
United Kingdom (651 publications)
Australia (72 publications)
USA (64 publications)

Most cited in 5 years

Found 
from chars
Publications found: 900
An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer’s disease: the role of apolipoprotein E
Lozupone M., Dibello V., Daniele A., Panza F.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder
Carnero Contentti E., Correale J.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Emerging treatments for sarcoma: from 2024 onward
Gómez-Puerto D., Cicala C.M., Valverde C., Serrano C.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Emerging biological treatments for asthma
Pastore D., Lupia C., D’Amato M., Bruni A., Garofalo E., Longhini F., Gallelli L., Vatrella A., Pelaia G., Pelaia C.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Mitapivat: a step forward across different hemolytic diseases
Hodroj M.H., Klim J., Charbel N., Taher A.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
FcRn inhibitors in the context of myasthenia gravis
Menon D., Bhandari V.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?
Harvey P.D.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Systemic therapy for Child-Pugh B patients with hepatocellular carcinoma
Mok K., Chen O., Yau J., Chan L.L., Chan S.L.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Seltorexant for major depressive disorder
Valentino K., Teopiz K.M., Wong S., Zhang M.C., Le G.H., Choi H., Ballum H., Dri C., Cheung W., McIntyre R.S.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Exploring emerging JAK inhibitors in the treatment of aicardi-goutières syndrome
Politano D., Tonduti D., Battini R., Fazzi E., Orcesi S.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0
Monoclonal antibodies in phase II and III trials for moderate to severe atopic dermatitis
Patel H.A., Tran L., Karagenova R., Feldman S.R.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0
ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?
Hansford J.R., Manoharan N., Bouche G., Ramaswamy V., Jabado N., Bouffet E.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0
Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results
Stella L., Hollande C., Merabet Y.B., Fakhouri H., Leclerc V., Ponziani F.R., Bouattour M.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion
Pan L., Nagib L., Ganguly S., Moorthy A., Tahir H.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 1
Current and emerging drug treatment strategies to tackle sickle cell anemia
Persaud Y., Leonard A., Rai P.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0

Top-100

Citing journals

200
400
600
800
1000
1200
Show all (70 more)
200
400
600
800
1000
1200

Citing publishers

2000
4000
6000
8000
10000
12000
Show all (70 more)
2000
4000
6000
8000
10000
12000

Publishing organizations

10
20
30
40
50
60
70
80
Show all (70 more)
10
20
30
40
50
60
70
80

Publishing organizations in 5 years

5
10
15
20
25
30
35
40
Show all (70 more)
5
10
15
20
25
30
35
40

Publishing countries

100
200
300
400
500
600
700
United Kingdom, 651, 33.03%
Australia, 72, 3.65%
USA, 64, 3.25%
China, 32, 1.62%
Israel, 21, 1.07%
Germany, 18, 0.91%
Ireland, 18, 0.91%
Netherlands, 15, 0.76%
Belgium, 13, 0.66%
Norway, 12, 0.61%
Sweden, 12, 0.61%
Spain, 11, 0.56%
Denmark, 9, 0.46%
Italy, 9, 0.46%
Singapore, 9, 0.46%
South Africa, 9, 0.46%
Canada, 8, 0.41%
India, 7, 0.36%
Republic of Korea, 7, 0.36%
Switzerland, 6, 0.3%
New Zealand, 5, 0.25%
Turkey, 5, 0.25%
Finland, 5, 0.25%
France, 4, 0.2%
Cyprus, 4, 0.2%
Chile, 4, 0.2%
Austria, 3, 0.15%
Greece, 3, 0.15%
Mexico, 3, 0.15%
Czech Republic, 3, 0.15%
Japan, 3, 0.15%
Russia, 2, 0.1%
Brazil, 2, 0.1%
Hungary, 2, 0.1%
Peru, 2, 0.1%
Ethiopia, 2, 0.1%
Portugal, 1, 0.05%
Argentina, 1, 0.05%
Brunei, 1, 0.05%
Iceland, 1, 0.05%
Kenya, 1, 0.05%
Colombia, 1, 0.05%
Costa Rica, 1, 0.05%
Lithuania, 1, 0.05%
Malaysia, 1, 0.05%
Nepal, 1, 0.05%
Nigeria, 1, 0.05%
Oman, 1, 0.05%
Pakistan, 1, 0.05%
Poland, 1, 0.05%
Romania, 1, 0.05%
Slovenia, 1, 0.05%
Tanzania, 1, 0.05%
Trinidad and Tobago, 1, 0.05%
Ecuador, 1, 0.05%
Eritrea, 1, 0.05%
Show all (26 more)
100
200
300
400
500
600
700

Publishing countries in 5 years

20
40
60
80
100
120
140
160
United Kingdom, 152, 55.88%
Australia, 25, 9.19%
China, 17, 6.25%
USA, 11, 4.04%
Ireland, 9, 3.31%
Spain, 9, 3.31%
Israel, 8, 2.94%
Germany, 6, 2.21%
Netherlands, 5, 1.84%
Denmark, 4, 1.47%
Republic of Korea, 4, 1.47%
Turkey, 4, 1.47%
Belgium, 3, 1.1%
India, 3, 1.1%
New Zealand, 3, 1.1%
Norway, 3, 1.1%
Singapore, 3, 1.1%
Sweden, 3, 1.1%
Brazil, 2, 0.74%
Hungary, 2, 0.74%
Greece, 2, 0.74%
Mexico, 2, 0.74%
Finland, 2, 0.74%
Chile, 2, 0.74%
Ethiopia, 2, 0.74%
Russia, 1, 0.37%
France, 1, 0.37%
Portugal, 1, 0.37%
Austria, 1, 0.37%
Argentina, 1, 0.37%
Brunei, 1, 0.37%
Italy, 1, 0.37%
Canada, 1, 0.37%
Kenya, 1, 0.37%
Cyprus, 1, 0.37%
Colombia, 1, 0.37%
Costa Rica, 1, 0.37%
Lithuania, 1, 0.37%
Nigeria, 1, 0.37%
Peru, 1, 0.37%
Romania, 1, 0.37%
Slovenia, 1, 0.37%
Tanzania, 1, 0.37%
Czech Republic, 1, 0.37%
Switzerland, 1, 0.37%
Ecuador, 1, 0.37%
South Africa, 1, 0.37%
Japan, 1, 0.37%
Show all (18 more)
20
40
60
80
100
120
140
160